Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.3%

5 terminated out of 79 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

34%

27 trials in Phase 3/4

Results Transparency

23%

8 of 35 completed with results

Key Signals

8 with results88% success

Data Visualizations

Phase Distribution

52Total
Not Applicable (15)
P 1 (2)
P 2 (8)
P 3 (11)
P 4 (16)

Trial Status

Completed35
Unknown22
Not Yet Recruiting6
Recruiting6
Terminated5
Withdrawn3

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 35 completed trials

Clinical Trials (79)

Showing 20 of 20 trials
NCT06500715Not ApplicableNot Yet RecruitingPrimary

Acupuncture as add-on to G-CSF for Febrile Neutropenia-related Hospitalization in Doxorubicin-treated Patients With Sarcoma

NCT07277387Not Yet RecruitingPrimary

Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia

NCT06918587Phase 1CompletedPrimary

A Comparative Evaluation of Pharmacokinetics and Immunogenicity.

NCT04948463Phase 4CompletedPrimary

Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

NCT03078010Phase 2Active Not Recruiting

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

NCT06697262Not ApplicableNot Yet Recruiting

Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutropenia

NCT07204522RecruitingPrimary

Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.

NCT06657183Not ApplicableRecruitingPrimary

ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy

NCT05815628RecruitingPrimary

Next-Generation-Sequencing Approach to Neutropenic Sepsis

NCT06988826Phase 4Not Yet RecruitingPrimary

Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia

NCT06342115Phase 4RecruitingPrimary

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

NCT06787326Active Not Recruiting

Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With Febrile Neutropenia

NCT05584930Not ApplicableCompleted

Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN)

NCT05784844Phase 4WithdrawnPrimary

Antimicrobial Revision in Persistent Febrile Neutropenia

NCT05786495Not ApplicableRecruitingPrimary

Short Antibiotic Treatment in High Risk Febrile Neutropenia

NCT06293677Phase 4RecruitingPrimary

Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance

NCT06450821Not ApplicableNot Yet Recruiting

PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications

NCT06278896Phase 3Not Yet Recruiting

Early Neutropenic Fever De-escalation of Antibiotics Study

NCT06116734Phase 3Unknown

Lapelga vs Gastrofil

NCT05311254Phase 3UnknownPrimary

A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia

Scroll to load more

Research Network

Activity Timeline